Moderna's COVID-19 vaccine: 13,194 people enroll for phase 3 trials

American biotechlogy company Moderna Inc has anunced that as of August 21, 13,194 people have enrolled to participate in COVE Phase 3 study of its COVID-19 vaccine, mRNA-1273. According to Moderna, purpose of study is to test company's vaccine candidate that may prevent illness after exposure to SARS-CoV-2 virus, which causes COVID-19. " study team is testing if vaccine can help immune system produce effective antibodies against SARS-CoV-2 virus so that, in case of infection, virus does t cause illness," company informed in a release. 

Re: COVID-19: Moderna, Pfizer To Include HIV+ Volunteers In Final St Of Vaccine Trials

Re: Trump ministration Signs $1.5 Billion Deal With Moderna For COVID-19 Vaccine Doses

Difference between rmal vaccines and mRNA-1273

Moderna furr informed that Black, Latis, American Indian, and Alaska native participants make up 18 per cent of all participants so far enrolled for Phase 3 study. For enrolling in study, participants must be 18 years of or above, y should be free from prior exposure to an investigational vaccine or treatment for COVID-19 and only healthy ults with previous history of COVID-19 or pre-existing medical conditions. Moderna's mRNA-1273 is different from typical vaccines, which are usually me from a weakened virus. However, mRNA-1273 is me from messenger ribonucleic acid (mRNA), a genetic code that helps body’s immune system make antibodies to fight virus by giving instructions to cells on how to make protein.

Re: Study: Moderna's Vaccine Candidate Protects Mice From Coronavirus Infection

According to Moderna, company has more than 1,900 participants enrolled in its infectious disease vaccine clinical studies under health authorities in United States, Europe, and Australia. company has so far tested its vaccine on more than 300 people and one has developed any side effects due to drug. Moderna has signed billions of dollars worth of deals with various governments, including United States to provide m with its COVID-19 vaccine if it shows positive results at end of ongoing clinical trials. 

Re: Swiss Ink Deal With Moderna For 4.5M Doses Of COVID Vaccine